Epstein-Barr Virus-Like Particles Without Viral DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing a vaccine against Epstein-Barr virus (EBV) lack efficiency and safety, as existing vaccines do not prevent infection and can potentially induce virus replication or latent infection due to the presence of viral genomes in virus-like particles (VLPs).
Innovation Solution
The production of Epstein-Barr virus-like particles (EB-VLPs) substantially free of EBV DNA, achieved by modifying the EBV genome to lack essential genes and using a suitable host cell to generate VLPs without viral replication or latent infection, ensuring the VLPs are empty and devoid of DNA, thereby enhancing safety and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional VLP production methods are used, then VLPs are produced, but viral genomes (DNA or RNA) are present in the VLPs, which can induce virus replication and latent infection
Solution Approach 1:
The invention extracts and removes the viral genome (DNA or RNA) from the virus-like particles while retaining the VLP structure. This is achieved by using mutant viruses that cannot package their genome into VLPs, thereby producing VLPs that are free of viral genetic material and cannot induce replication or latent infection.
Solution Approach 2:
The invention converts the harmful presence of viral genomes in VLPs into a benefit by deliberately using mutant viruses with defective genome packaging capabilities. These mutants, which would normally be considered defective or harmful, are instead utilized to produce safe VLPs that cannot replicate but maintain immunogenicity.
2Reliability
If peptidic vaccines are used, then they are safe, but they do not prevent EBV infection effectively
Solution Approach 1:
The invention creates a composite vaccine structure by combining the safety of peptide-based approaches with the enhanced immunogenicity of VLPs. The resulting EBV-VLPs incorporate viral structural proteins that self-assemble into particle forms, providing both the safety profile needed for vaccination and the structural complexity required to elicit strong protective immune responses.
3Productivity
If VLPs containing viral genomes are used, then they can stimulate immune response, but they risk inducing virus replication and latent infection
Solution Approach 1:
The invention extracts and removes the viral genome (DNA or RNA) from the virus-like particles while retaining the VLP structure. This is achieved by using mutant viruses that cannot package their genome into VLPs, thereby producing VLPs that are free of viral genetic material and cannot induce replication or latent infection.
Solution Approach 2:
The invention creates accurate copies of the viral particle structure (VLPs) without including the harmful viral genome. These VLP copies mimic the native virus morphology and surface proteins, enabling them to stimulate the immune system effectively while lacking the genetic material necessary for replication and infection.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing said EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising said EB-VLPs.